Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function

Blood ◽  
2005 ◽  
Vol 106 (2) ◽  
pp. 746-748 ◽  
Author(s):  
Lénaïck Détivaud ◽  
Elizabeta Nemeth ◽  
Karim Boudjema ◽  
Bruno Turlin ◽  
Marie-Bérengère Troadec ◽  
...  

Abstract Hepcidin, a key regulator of iron metabolism, is synthesized by the liver. Hepcidin binds to the iron exporter ferroportin to regulate the release of iron into plasma from macrophages, hepatocytes, and enterocytes. We analyzed liver samples from patients undergoing hepatic surgery for cancer or receiving liver transplants and analyzed correlations between clinical parameters and liver hepcidin mRNA and urinary hepcidin concentrations. Despite the many potential confounding influences, urinary hepcidin concentrations significantly correlated with hepatic hepcidin mRNA concentrations, indicating that hepcidin quantification in urine is a valid approach to evaluate hepcidin expression. Moreover, we found in humans that hepcidin levels correlated with hepatic iron stores and hemoglobin levels and may also be affected by hepatic dysfunction. (Blood. 2005;106:746-748)

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 3578-3578
Author(s):  
Richard S. Ajioka ◽  
Ryan R. Gillespie ◽  
James P. Kushner

Abstract Dietary iron absorption by enterocytes is mediated by a ferrous transporter (DMT1) and possibly a ferric reductase (Cbyrd1). The role of Cbyrd1 is uncertain, as a knockout mouse has no defect in absorption (Gunshin et al. Blood, 2005, June 16, Epub). Transfer of iron to plasma is mediated by ferroportin (FPN). FPN’s residence on the basolateral membrane is regulated by hepcidin (Nemeth et al. Science 2004, 306:2090–3). Iron absorption responds to erythropoiesis, hypoxia and iron stores. A dietary iron content of 120 mg/kg consumed will maintain hepatic iron stores near that of mice found in the wild. Mice will grow and breed given diets containing 35 mg/kg. Commercial mouse chow iron content ranges from 200–350 mg/kg. We studied the effects of diets containing 2, 35, 120, 350 and 2000 mg iron/kg on iron absorption, liver and spleen iron content and transcriptional levels of DMT1, FPN and hepcidin in A/J mice. Mice were weaned at 3 weeks of age and groups of 8 animals were placed on one of the 5 diets for 4 weeks. No differences between groups were noted in hematocrit, hemoglobin and MCV. Mean hepatic iron content was 52.7 ±3.7 ug/g (wet wt) in mice fed the 2 mg/kg diet. Mean hepatic iron content was 560 ±23.7 ug/g in mice fed the 2000 mg/kg diet. There was no difference in hepatic iron content in mice fed intermediate iron diets (35–350 mg/kg). Mean hepatic iron concentration in these groups was 110 ±3 ug/g. Mean spleen iron content was 132 ±12.2 ug/g (wet wt) in mice maintained on 2 mg/kg. Mean spleen iron content was 598 ±49 ug/g in mice fed the 2000 mg/kg diet. There was no difference in spleen iron content in mice maintained on intermediate iron diets (mean 359 ±10 ug/g). These data indicate that mice maintain constant levels of hepatic and splenic iron over a ten-fold range in dietary iron content. Iron absorption was measured as percent of a measured dose of 59Fe (5 ug total) remaining in the carcass (minus the GI tract) 24 h after administration by gavage. Absorption was inversely proportional to dietary iron content. Mean absorption was 86% ±4 in the group on the 2 mg/kg diet, 42% ±3 on the 35 mg/kg diet, 26% ±7 on the 120 mg/kg diet, 19% ±4 on the 350 mg/kg diet and 6% ±1 on the 2000 mg/kg diet. Transcript levels of hepcidin, DMT1 and FPN were measured by real-time PCR and normalized to beta actin mRNA. Liver hepcidin expression was 20-fold greater in mice on the 2000 mg/kg diet than in mice on the 2 mg/kg diet (3900 ±1021 copies/actin copy vs. 198 ±47). Hepcidin expression did not differ in mice on intermediate diets (745 ±147 copies). Enterocytes were isolated from everted gut explants by elution in EDTA. Transcript levels of enterocyte DMT1 and FPN were 4566 ±SEM and 236 ±SEM copies respectively in mice on the 2 mg/kg diet. No detectable transcripts were found in mice on the 2000 mg/kg diet. Enterocyte transcript levels for DMT1 and FPN were no different in groups on intermediate iron diets (17 ±2 copies and 20 ±9 copies respectively). These data indicate that tissue iron content, hepcidin, DMT1 and FPN remain constant over a ten-fold range in dietary iron and only vary at extremes, while iron absorption is inversely proportional to dietary iron. The data also suggest that dietary iron, within defined limits, regulates iron absorption by a mechanism intrinsic to the enterocyte.


Blood ◽  
2012 ◽  
Vol 120 (16) ◽  
pp. 3336-3344 ◽  
Author(s):  
Anu Laitala ◽  
Ellinoora Aro ◽  
Gail Walkinshaw ◽  
Joni M. Mäki ◽  
Maarit Rossi ◽  
...  

AbstractAn endoplasmic reticulum transmembrane prolyl 4-hydroxylase (P4H-TM) is able to hydroxylate the α subunit of the hypoxia-inducible factor (HIF) in vitro and in cultured cells, but nothing is known about its roles in mammalian erythropoiesis. We studied such roles here by administering a HIF-P4H inhibitor, FG-4497, to P4h-tm−/− mice. This caused larger increases in serum Epo concentration and kidney but not liver Hif-1α and Hif-2α protein and Epo mRNA levels than in wild-type mice, while the liver Hepcidin mRNA level was lower in the P4h-tm−/− mice than in the wild-type. Similar, but not identical, differences were also seen between FG-4497–treated Hif-p4h-2 hypomorphic (Hif-p4h-2gt/gt) and Hif-p4h-3−/− mice versus wild-type mice. FG-4497 administration increased hemoglobin and hematocrit values similarly in the P4h-tm−/− and wild-type mice, but caused higher increases in both values in the Hif-p4h-2gt/gt mice and in hematocrit value in the Hif-p4h-3−/− mice than in the wild-type. Hif-p4h-2gt/gt/P4h-tm−/− double gene-modified mice nevertheless had increased hemoglobin and hematocrit values without any FG-4497 administration, although no such abnormalities were seen in the Hif-p4h-2gt/gt or P4h-tm−/− mice. Our data thus indicate that P4H-TM plays a role in the regulation of EPO production, hepcidin expression, and erythropoiesis.


1994 ◽  
Vol 21 (6) ◽  
pp. 1109-1112 ◽  
Author(s):  
Adrian M. Di Bisceglie ◽  
Bruce R. Bacon ◽  
David E. Kleiner ◽  
Jay H. Hoofnagle

PEDIATRICS ◽  
1972 ◽  
Vol 50 (1) ◽  
pp. 100-111
Author(s):  
Philip Sunshine ◽  
Jeffrey E. Lindenbaum ◽  
Harvey L. Levy ◽  
John M. Freeman

A 9-year-old girl with vomiting, changes in behavior, coma, and evidence of hepatic dysfunction at 3½ years of age was found to have hyperammonemia and decreased activity of liver ornithine transcarbamylase. When her dietary protein was reduced, she had improvement in her clinical condition and a return to normal of all hepatic function indices. Despite a defect in an enzyme of ornithine metabolism, she did not have hyperaminoacidemia, specifically hyperornithinemia, even when she had hyperammonemia. When she ingested a large amount of ornithine (300 mg/kg) she developed hyperornithinemia and hyperornithinuria. She also had orotic aciduria despite having normal activities of red cell orotidylic decarboxylase and pyrophosphorylase. Treatment with a low protein diet and citric acid supplements has been successful in preventing hyperammonemia and promoting growth and development.


2000 ◽  
Vol 11 (5) ◽  
pp. 336-337 ◽  
Author(s):  
S Clarke ◽  
P Harrington ◽  
C Condon ◽  
D Kelleher ◽  
O P Smith ◽  
...  

The aetiology of hepatic dysfunction in patients with HIV infection is multifactorial. Re-activation of hepatitis C infection, drug toxicity, and opportunistic infections are all potential causes. Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy for the treatment of HIV infection. It is associated with a significant incidence of hepatotoxicity, usually occurring in the initial month of therapy. We report the case of a 49-year-old man who developed NVP-induced prolonged hepatotoxicity 5 months after commencing antiretroviral therapy.


1997 ◽  
Vol 43 (8) ◽  
pp. 1457-1459 ◽  
Author(s):  
Meira Fields ◽  
Isabelle Bureau ◽  
Charles G Lewis

1988 ◽  
Vol 12 (1) ◽  
pp. 7-13 ◽  
Author(s):  
Michael G. Irving ◽  
June W. Halliday ◽  
Lawrie W. Powell
Keyword(s):  

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 512-512
Author(s):  
Lan Lin ◽  
Y. Paul Goldberg ◽  
Tomas Ganz

Abstract Human genetic studies identified HJV (also called HFE2) as the major cause for juvenile hemochromatosis (JH). Patients with HJV hemochromatosis have low urinary levels of hepcidin, the principal iron-regulatory hormone secreted by the liver. We attempted to establish the specific roles of HJV in iron metabolism, especially its relationship with hepcidin. Translation of the genomic sequence indicated a C-terminal GPI anchor for the protein product of HJV, hemojuvelin. This suggested that hemojuvelin may have either a soluble or a cell-associated form. In human hepatoma cell line Hep3B, knockdown of cellular HJV by siRNA decreased hepcidin expression, independently of the IL-6 pathway. Intriguingly, the addition of recombinant soluble hemojuvelin (rs-hemojuvelin) also suppressed hepcidin expression in primary human hepatocytes, in a log-linear dose-dependent manner, suggesting competition between soluble and cell-associated forms of hemojuvelin. Soluble hemojuvelin was found in human sera at concentrations similar to those required to suppress hepcidin mRNA in vitro. In cells engineered to express hemojuvelin, soluble hemojuvelin release was progressively inhibited by increasing iron or holotransferrin concentrations. Our study suggests that soluble and cell-associated hemojuvelin reciprocally regulate hepcidin mRNA levels, and that hemojuvelin may serve as a molecular messenger for iron homeostasis. Even in hepatocytes stimulated with IL-6, we observed strong suppression of hepcidin mRNA by rs-hemojuvelin. If rs-hemojuvelin or its active fragments also suppress hepcidin production in vivo, they could be used to alleviate anemia of inflammation.


Sign in / Sign up

Export Citation Format

Share Document